In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, Zenas Biopharma Inc’s stock clocked out at $36.15, up 3.08% from its previous closing price of $35.07. In other words, the price has increased by $3.08 from its previous closing price. On the day, 1.39 million shares were traded. ZBIO stock price reached its highest trading level at $37.97 during the session, while it also had its lowest trading level at $35.245.
Ratios:
To gain a deeper understanding of ZBIO’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.66 and its Current Ratio is at 5.66. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In the most recent recommendation for this company, Wedbush on March 20, 2025, initiated with a Outperform rating and assigned the stock a target price of $35.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $19. On December 16, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.H.C. Wainwright initiated its Buy rating on December 16, 2024, with a $30 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 09 ’25 when Nunn Jason Raleigh bought 63,158 shares for $19.00 per share. The transaction valued at 1,200,002 led to the insider holds 1,173,395 shares of the business.
SR ONE CAPITAL MANAGEMENT, LLC bought 126,315 shares of ZBIO for $2,399,985 on Oct 09 ’25. The 10% Owner now owns 1,917,895 shares after completing the transaction at $19.00 per share. On Oct 09 ’25, another insider, ENRIGHT PATRICK G, who serves as the Director of the company, bought 105,265 shares for $19.00 each. As a result, the insider paid 2,000,035 and bolstered with 1,832,669 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZBIO now has a Market Capitalization of 1940502016 and an Enterprise Value of 1650415872. For the stock, the TTM Price-to-Sale (P/S) ratio is 129.37 while its Price-to-Book (P/B) ratio in mrq is 7.77. Its current Enterprise Value per Revenue stands at 110.028 whereas that against EBITDA is -8.437.
Stock Price History:
The Beta on a monthly basis for ZBIO is -1.22, which has changed by 2.7774296 over the last 52 weeks, in comparison to a change of 0.14402747 over the same period for the S&P500. Over the past 52 weeks, ZBIO has reached a high of $41.50, while it has fallen to a 52-week low of $5.83. The 50-Day Moving Average of the stock is 8.90%, while the 200-Day Moving Average is calculated to be 100.46%.
Shares Statistics:
It appears that ZBIO traded 420.35K shares on average per day over the past three months and 418190 shares per day over the past ten days. A total of 42.21M shares are outstanding, with a floating share count of 21.93M. Insiders hold about 59.14% of the company’s shares, while institutions hold 31.11% stake in the company. Shares short for ZBIO as of 1764288000 were 4858909 with a Short Ratio of 11.56, compared to 1761868800 on 4766849. Therefore, it implies a Short% of Shares Outstanding of 4858909 and a Short% of Float of 12.0699994.
